Cargando…

Structure–activity exploration of a small-molecule Lipid II inhibitor

We have recently identified low-molecular weight compounds that act as inhibitors of Lipid II, an essential precursor of bacterial cell wall biosynthesis. Lipid II comprises specialized lipid (bactoprenol) linked to a hydrophilic head group consisting of a peptidoglycan subunit (N-acetyl glucosamine...

Descripción completa

Detalles Bibliográficos
Autores principales: Fletcher, Steven, Yu, Wenbo, Huang, Jing, Kwasny, Steven M, Chauhan, Jay, Opperman, Timothy J, MacKerell, Alexander D, de Leeuw, Erik PH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422293/
https://www.ncbi.nlm.nih.gov/pubmed/25987836
http://dx.doi.org/10.2147/DDDT.S79504
_version_ 1782370034077663232
author Fletcher, Steven
Yu, Wenbo
Huang, Jing
Kwasny, Steven M
Chauhan, Jay
Opperman, Timothy J
MacKerell, Alexander D
de Leeuw, Erik PH
author_facet Fletcher, Steven
Yu, Wenbo
Huang, Jing
Kwasny, Steven M
Chauhan, Jay
Opperman, Timothy J
MacKerell, Alexander D
de Leeuw, Erik PH
author_sort Fletcher, Steven
collection PubMed
description We have recently identified low-molecular weight compounds that act as inhibitors of Lipid II, an essential precursor of bacterial cell wall biosynthesis. Lipid II comprises specialized lipid (bactoprenol) linked to a hydrophilic head group consisting of a peptidoglycan subunit (N-acetyl glucosamine [GlcNAc]–N-acetyl muramic acid [MurNAc] disaccharide coupled to a short pentapeptide moiety) via a pyrophosphate. One of our lead compounds, a diphenyl-trimethyl indolene pyrylium, termed BAS00127538, interacts with the MurNAc moiety and the isoprenyl tail of Lipid II. Here, we report on the structure–activity relationship of BAS00127538 derivatives obtained by in silico analyses and de novo chemical synthesis. Our results indicate that Lipid II binding and bacterial killing are related to three features: the diphenyl moiety, the indolene moiety, and the positive charge of the pyrylium. Replacement of the pyrylium moiety with an N-methyl pyridinium, which may have importance in stability of the molecule, did not alter Lipid II binding or antibacterial potency.
format Online
Article
Text
id pubmed-4422293
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44222932015-05-18 Structure–activity exploration of a small-molecule Lipid II inhibitor Fletcher, Steven Yu, Wenbo Huang, Jing Kwasny, Steven M Chauhan, Jay Opperman, Timothy J MacKerell, Alexander D de Leeuw, Erik PH Drug Des Devel Ther Original Research We have recently identified low-molecular weight compounds that act as inhibitors of Lipid II, an essential precursor of bacterial cell wall biosynthesis. Lipid II comprises specialized lipid (bactoprenol) linked to a hydrophilic head group consisting of a peptidoglycan subunit (N-acetyl glucosamine [GlcNAc]–N-acetyl muramic acid [MurNAc] disaccharide coupled to a short pentapeptide moiety) via a pyrophosphate. One of our lead compounds, a diphenyl-trimethyl indolene pyrylium, termed BAS00127538, interacts with the MurNAc moiety and the isoprenyl tail of Lipid II. Here, we report on the structure–activity relationship of BAS00127538 derivatives obtained by in silico analyses and de novo chemical synthesis. Our results indicate that Lipid II binding and bacterial killing are related to three features: the diphenyl moiety, the indolene moiety, and the positive charge of the pyrylium. Replacement of the pyrylium moiety with an N-methyl pyridinium, which may have importance in stability of the molecule, did not alter Lipid II binding or antibacterial potency. Dove Medical Press 2015-04-24 /pmc/articles/PMC4422293/ /pubmed/25987836 http://dx.doi.org/10.2147/DDDT.S79504 Text en © 2015 Fletcher et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Fletcher, Steven
Yu, Wenbo
Huang, Jing
Kwasny, Steven M
Chauhan, Jay
Opperman, Timothy J
MacKerell, Alexander D
de Leeuw, Erik PH
Structure–activity exploration of a small-molecule Lipid II inhibitor
title Structure–activity exploration of a small-molecule Lipid II inhibitor
title_full Structure–activity exploration of a small-molecule Lipid II inhibitor
title_fullStr Structure–activity exploration of a small-molecule Lipid II inhibitor
title_full_unstemmed Structure–activity exploration of a small-molecule Lipid II inhibitor
title_short Structure–activity exploration of a small-molecule Lipid II inhibitor
title_sort structure–activity exploration of a small-molecule lipid ii inhibitor
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422293/
https://www.ncbi.nlm.nih.gov/pubmed/25987836
http://dx.doi.org/10.2147/DDDT.S79504
work_keys_str_mv AT fletchersteven structureactivityexplorationofasmallmoleculelipidiiinhibitor
AT yuwenbo structureactivityexplorationofasmallmoleculelipidiiinhibitor
AT huangjing structureactivityexplorationofasmallmoleculelipidiiinhibitor
AT kwasnystevenm structureactivityexplorationofasmallmoleculelipidiiinhibitor
AT chauhanjay structureactivityexplorationofasmallmoleculelipidiiinhibitor
AT oppermantimothyj structureactivityexplorationofasmallmoleculelipidiiinhibitor
AT mackerellalexanderd structureactivityexplorationofasmallmoleculelipidiiinhibitor
AT deleeuwerikph structureactivityexplorationofasmallmoleculelipidiiinhibitor